ProfileGDS5678 / 1419279_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 95% 95% 95% 95% 96% 96% 95% 95% 95% 95% 95% 95% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.5534795
GSM967853U87-EV human glioblastoma xenograft - Control 28.5701695
GSM967854U87-EV human glioblastoma xenograft - Control 38.4441695
GSM967855U87-EV human glioblastoma xenograft - Control 48.7817295
GSM967856U87-EV human glioblastoma xenograft - Control 58.5005195
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.6049496
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.6086896
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5756295
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.5743695
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.3663795
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.5196295
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.5089895
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.5693995
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.5268295